AZN
-
AstraZeneca shakes up R&D division with 1,600 staff cuts and shift to biotech hot spots (video)
AstraZeneca (NYSE:AZN) is revamping its research and development divisions to improve drug development by cutting […]
-
Amylin acquisition marks new chapter in Bristol-Myers Squibb, AstraZeneca diabetes alliance
Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest […]
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
First, personalized medicine; next, personalized health insurance
Big data’s surging tide of information on medicines, patients and outcomes is changing how pharmaceutical […]
-
AZN’s outgoing CEO prompts question: what makes a good pharma CEO?
David Brennan’s move to retire as AstraZeneca’s CEO in June did not come as a surprise to those who had been urging for a change at the top over the company’s drug development shortcomings. In an industry that walks a tightrope between innovation and regulation and the financial considerations that frame them, there are two critical characteristics that can undermine a CEO: being too bold or not bold enough. Brennan was a bit of both.
-
AstraZeneca’s $1 billion deal adds phase 3 gout drug
AstraZeneca (NYSE:AZN) has agreed to acquire a biotechnology company with a gout drug in phase […]
-
AstraZeneca CEO faces familiar question on how to grow
Amidst calls by shareholders for a management shakeup, AstraZeneca (NYSE: AZN) CEO David Brennen sought […]
-
AstraZeneca and Amgen collaborate on treatments for inflammatory diseases
AstraZeneca (NYSE:AZN) and Amgen (NYSE:AMGN) will collaborate on five monoclonal antibodies to treat inflammatory diseases […]
-
FDA’s new statin label warning about diabetes risk may have little effect
In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physicians […]
-
Tale of 2 pharmas: GSK’s pipeline shows promise, AZN’s prospects dim
GlaxoSmithKline (NYSE:GSK) released fourth-quarter 2011 and full-year financial results Tuesday, which happens to be Charles […]
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Big Pharma shrink continues with more AstraZeneca job cuts
AstraZeneca (NYSE:AZN) is cutting more than 7,300 jobs across its global operations as part of […]
-
FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZeneca
Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 diabetes has been […]
-
AstraZeneca takes on TRGT’s Alzheimer’s disease drug candidate
Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months […]
-
Neoprobe: Alzheimer’s diagnosis agent has market potential exceeding $1B
Neoprobe‘s (NYSE Amex:NEOP) newly licensed drug candidate that could aid in the diagnosis of Alzheimer’s […]
-
Neoprobe licenses Alzheimer’s diagnosis imaging agent from AZN
Neoprobe (NYSE Amex:NEOP) has licensed from AstraZeneca (NYSE:AZN) the worldwide rights to an imaging drug […]